Elaina M Gartner

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer
    Elaina M Gartner
    Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48108, USA
    Invest New Drugs 27:159-65. 2009
  2. ncbi A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
    Elaina M Gartner
    Karmanos Cancer Institute, Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
    Breast Cancer Res Treat 131:933-7. 2012
  3. ncbi Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future
    Elaina M Gartner
    Departments of Internal Medicine and daggerPharmacology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA
    Cancer J 16:83-90. 2010

Detail Information

Publications3

  1. ncbi A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer
    Elaina M Gartner
    Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48108, USA
    Invest New Drugs 27:159-65. 2009
    ..TM can be safely added to IFL without compromising dose intensity or diminishing the expected RR. Changes in serum VEGF, IL-8, and IL-6 after treatment may directly reflect changes in CRC tissue angiogenesis...
  2. ncbi A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
    Elaina M Gartner
    Karmanos Cancer Institute, Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
    Breast Cancer Res Treat 131:933-7. 2012
    ..Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary. Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients...
  3. ncbi Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future
    Elaina M Gartner
    Departments of Internal Medicine and daggerPharmacology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA
    Cancer J 16:83-90. 2010
    ..The most recent data from the clinical trials of olaparib (AZD2281, KU-0059436), BSI-201, AG014699, ABT-888, and INO-1001 and descriptions of ongoing studies are also presented...